Prognostic value of lactate dehydrogenase-to-albumin ratio in metastatic/recurrent pancreatic cancer treated with first-line gemcitabine plus nab-paclitaxel: a single-center retrospective cohort study
Open Access
- 1 June 2026
- journal article
- Published by AME Publishing Company in Journal of Gastrointestinal Oncology
- Vol. 17 (3) , 174
Abstract
Background: Prognostic stratification at the initiation of chemotherapy is clinically important in patients with metastatic or recurrent unresectable pancreatic cancer. The lactate dehydrogenase-to-albumin ratio (LAR) is an objective blood-based index that combines tumor-associated activities with systemic conditions of the host; however, evidence of its usefulness as a prognostic index in patients receiving first-line gemcitabine plus nab-paclitaxel (GnP) remains limited. In this study, we evaluated the prognostic value of baseline LAR in these patients. Methods: This single-center retrospective cohort study included consecutive patients with metastatic or recurrent unresectable pancreatic cancer who underwent first-line GnP between 2015 and 2024. Baseline LAR was calculated from laboratory data obtained within 7 days before treatment initiation, and neutrophil-to-lymphocyte ratio (NLR) was evaluated as a comparative inflammatory marker. The primary analysis evaluated the association between baseline LAR and overall survival (OS) using prespecified multivariable Cox proportional hazards models. The functional form of LAR was examined using restricted cubic splines (RCS). Kaplan-Meier curves were then presented to visualize risk stratification by combining Eastern Cooperative Oncology Group performance status (ECOG PS) with LAR. The incremental prognostic performance beyond the base clinical model was evaluated using model fit and discrimination metrics, with bootstrap internal validation. Results: The final analytic cohort comprised 205 patients (median age, 67 years; 63.9% men). The median baseline LAR was 4.94. In the prespecified multivariable model, ECOG PS and LAR were independently associated with OS [PS 2 vs. 0: hazard ratio (HR), 2.38; 95% confidence interval (CI), 1.28–4.42; LAR per 1-standard deviation (SD) increase: HR, 1.29; 95% CI, 1.09–1.52]. RCS analysis demonstrated a significant overall association without evidence of nonlinearity (overall P=0.03; nonlinear P=0.71). Kaplan-Meier curves for four risk groups defined by PS (0–1 vs. 2) and LAR (below vs. at/above the median) showed significant separation (log-rank PConclusions: Baseline LAR was independently associated with OS after adjustment for ECOG PS in patients receiving first-line GnP. Therefore, PS combined with LAR may enable simple prognostic stratification at treatment initiation, pending confirmation in future external validation cohorts.Keywords
This publication has 20 references indexed in Scilit:
- The usefulness of lactate dehydrogenase measurements in current oncological practiceCellular & Molecular Biology Letters, 2020
- Inter-rater reliability in performance status assessment among healthcare professionals: an updated systematic review and meta-analysisSupportive Care in Cancer, 2020
- Lactate dehydrogenase: a marker of diminished antitumor immunityOncoImmunology, 2020
- Comparing Physician and Nurse Eastern Cooperative Oncology Group Performance Status (ECOG-PS) Ratings as Predictors of Clinical Outcomes in Patients with CancerThe Oncologist, 2019
- A meta-analysis of the impact of neutrophil-to-lymphocyte ratio on treatment outcomes after radiotherapy for solid tumorsMedicine, 2019
- Prognostic factors for progression-free and overall survival in advanced biliary tract cancerAnnals of Oncology, 2015
- Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: a meta-analysisScientific Reports, 2015
- Performance Status and Smoking Status Are Independent Favorable Prognostic Factors for Survival in Non-small Cell Lung Cancer: A Comprehensive Analysis of 26,957 Patients with NSCLCJournal of Thoracic Oncology, 2010
- The cost of dichotomising continuous variablesBMJ, 2006
- Performance status assessment in cancer patients. An inter-observer variability studyBritish Journal of Cancer, 1993